Retreatment With CTL019/CTL119
ConditionLymphoma, B-Cell
Trial statusNot yet recruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity of Pennsylvania
About this trial
This research study is designed to evaluate the effects of retreatment with CTL019/CTL119 in patients with late relapse of B-cell lymphomas.
Eligibility criteria
Qualifiers
Diffuse Large B-Cell Lymphoma or Follicular lymphoma, previously identified as CD19+
Previously treated on UPCC13413/ NCT02030834 with CTL019/CTL119, with historical manufactured product available at Penn for reinfusion
Previous complete response to CAR T-cells with a duration ≥ 6 months (defined as 168 days)
No available curative treatment options (such as autologous or allogeneic HSCT) with limited prognosis (several months to < 2 year survival) with currently available therapies.
Disqualifiers
Uncontrolled active infection.
Active hepatitis B or hepatitis C infection.
Any uncontrolled active medical disorder that would preclude participation as outlined.
Class III/IV cardiovascular disability according to the New York Heart Association Classification (see Appendix 1).
Trial design
Treatments tested in this trial
- CD19 redirected autologous T cells (CTL019 or CTL119 cells)
Treatment groups
12 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov